Trial | NCT00330083  Report issue

Title

Safety of ALK Ragweed Tablet
A RANDOMIZED, MULTIPLE DOSE, DOSE-ESCALATION, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE I TRIAL INVESTIGATING THE OPTIMAL SAFE DOSE OF ALK RAGWEED TABLET AMBROSIA ARTEMISIIFOLIA IN ADULT SUBJECTS WITH SEASONAL RHINOCONJUNCTIVITIS CAUSED BY RAGWEED POLLEN ALLERGY

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    72
This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults
Study Started
May 31
2006
Last Update
Sep 21
2007
Estimate

Biological ALK Ragweed Tablet

Criteria 

Inclusion Criteria:

Ragweed pollen induced rhinoconjunctivitis
Adults of either sex (18-50 years of age)
Positive skin prick test to ragweed

Exclusion Criteria:

Previous treatment with immunotherapy
No Results Posted